Skip to content

LYmphangiogenesis FacTors in Heart Failure States

LYmphangiogenesis FacTors in Heart Failure States (LYFT-HF Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03141567
Acronym
LYFT-HF
Enrollment
100
Registered
2017-05-05
Start date
2017-05-18
Completion date
2023-01-24
Last updated
2023-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Heart Failure With Normal Ejection Fraction, Heart Failure With Reduced Ejection Fraction

Keywords

Lymphangiogenesis, Heart Failure

Brief summary

Heart failure often causes fluid to accumulate in the body, leading to congestion and swelling. However, some people who have had heart failure for a long time seem to have very little congestion or swelling, even when the heart failure is poorly treated. The investigators think that this is because lymphatic vessels are able to grow and remove fluid to prevent congestion. The investigators do not know how lymphatic vessels grow. This study will investigate the blood levels of various proteins to try to figure out how the lymph vessels of people with long-standing heart failure might grow.

Interventions

None listed

Sponsors

Medical University of South Carolina
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Undergoing clinically indicated right heart catheterization.

Exclusion criteria

* Unable to provide consent. * Use of medications which may alter lymphangiogenesis factor expression within 365 days * Thalidomide, lenalidomide, pomalidomide * Bevacizumab * Any cytotoxic chemotherapy agents * Pregnant * Any potentially pregnant patient (based on age and gender) undergoes Beta Human chorionic gonadotropin testing as standard of care prior to any right heart catheterization. * Active cancer within 365 days * Diagnosis of familial or secondary lymphedema * Treatment of active bacterial infection within 7 days * Active inflammatory rheumatologic disease requiring anti-inflammatory therapy administration within 60 days * Conditions * Systemic lupus erythematosus * Rheumatoid arthritis * Scleroderma * Inflammatory myositis * Vasculitis * Behcet's disease

Design outcomes

Primary

MeasureTime frameDescription
Vascular Endothelial Growth Factor (VEGF) LevelsAt time of right heart catheterizationVEGF levels in systemic venous, pulmonary arterial, and pulmonary venous samples in participants with left heart failure versus those without left heart failure.

Secondary

MeasureTime frameDescription
Lymphangiogenesis factors and Pulmonary Capillary Wedge Pressure (PCWP)At time of right heart catheterizationCorrelation between above lymphangiogenesis factors and pulmonary capillary wedge pressure, right atrial pressure, and cardiac output gathered from right heart catheterization.
Lymphangiogenesis and Heart failure severityAt time of right heart catheterizationCorrelation between lymphangiogenesis factors and heart failure symptom severity as determined by the Kansas City Cardiomyopathy Questionnaire
Lymphangiogenesis and 6 minute hall walkAt time of right heart catheterizationCorrelation between lymphangiogenesis factors and 6 minute walk distance.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026